188 research outputs found

    Complete genome sequence of human T-cell lymphotropic type 1 from patients with different clinical profiles, including infective dermatitis

    No full text
    Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil / Escola Bahiana de Medicina e Sa├║de P├║blica. Salvador, BA, Brazil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil / Universidade Federal da Bahia, Salvador, BA, Brazil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil.Minist├ęrio da Sa├║de. Secretaria de Vigil├óncia em Sa├║de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Minist├ęrio da Sa├║de. Secretaria de Vigil├óncia em Sa├║de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Minist├ęrio da Sa├║de. Secretaria de Vigil├óncia em Sa├║de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Escola Bahiana de Medicina e Sa├║de P├║blica. Salvador, BA, Brazil.Funda├ž├úo Hemocentro de Ribeir├úo Preto. S├úo Paulo, SP, Brazil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil / Bellvitge Biomedical Research Institute. Catalan Institute of Oncology. Barcelona, Spain.Universidade Federal da Bahia. Salvador, BA, Brazil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil / Universidade Federal da Bahia. Salvador, BA, Brazil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil / Escola Bahiana de Medicina e Sa├║de P├║blica. Salvador, BA, Brazil.Universidade Cat├│lica do Salvador. Salvador, BA, Brazil.Universidade Federal da Bahia. Salvador, BA, Brazil.Minist├ęrio da Sa├║de. Secretaria de Vigil├óncia em Sa├║de. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Salvador, BA, Brazil.The HTLV-1 is the first human retrovirus and is associated with several clinical syndromes, however, the pathogenesis of these clinical manifestations is still not fully understood. Furthermore, there are few complete genomes publicly available, about 0.12 complete genomes per 10,000 infected individuals and the databases have a major deficiency of sequences information. This study generated and characterized 31 HTLV-1 complete genomes sequences derived from individuals with Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM), Adult T-cell leukemia/lymphoma (ATL), infective dermatitis associated to HTLV-1 (IDH) and asymptomatic patients. These sequences are associated to clinical and epidemiological information about the patients. The sequencing data generated on Ion Torrent PGM platform were assembled and mapped against the reference HTLV-1 genome. These sequences were genotyped as Cosmopolitan subtype, Transcontinental subgroup. We identified the variants in the coding regions of the genome of the different clinical profiles, however, no statistical relation was detected. This study contributed to increase of HTLV-1 complete genomes in the world. Furthermore, to better investigate the contribution of HTLV-1 mutations for the disease outcome it is necessary to evaluate the interaction of the viral genome and characteristics of the human host

    Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

    No full text
    Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2018-06-26T17:42:52Z No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2018-06-26T17:55:09Z (GMT) No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5)Made available in DSpace on 2018-06-26T17:55:09Z (GMT). No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5) Previous issue date: 2018Universidade Federal da Bahia. P├│s-Gradua├ž├úo em Ci├¬ncias da Sa├║de. Salvador, BA, Brasil / Universidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Imunologia. Salvador, BA, Brasil / Universidade Estadual de Feira de Santana. Feira de Santana, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. P├│s-Gradua├ž├úo em Ci├¬ncias da Sa├║de. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. P├│s-Gradua├ž├úo em Ci├¬ncias da Sa├║de. Salvador, BA, BrasilUniversidade Federal da Bahia. P├│s-Gradua├ž├úo em Ci├¬ncias da Sa├║de. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universit├írio Prof. Edgard Santos. Servi├žo de Urologia. Salvador, BA, Brasil / Funda├ž├úo Oswaldo Cruz. Instituto Gon├žalo Moniz. Laborat├│rio de Pesquisa Cl├şnica. Salvador, BA, Brasil / Instituto Nacional de Ci├¬ncia e Tecnologia de Doenc┬Şas Tropicais. Salvador, BA, BrasilTo evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservativetreatment with anticholinergic or physical therapy. They received 200Ui of onabotulinum-toxin type A intravesically and were evaluated by overactive bladder symptoms score(OABSS) and KingÔÇÖs Health Questionnaire.Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them hadconfirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. Themedian and range of the OABSS was 13 (12ÔÇô15) before therapy and decreased to 1.0 (0ÔÇô12)on day 30 and to 03 (0ÔÇô14) on day 90 (p < 0.0001). There was a significant improvement in 8 ofthe 9 domains of the KingÔÇÖs Health Questionnaire after the intervention. Hematuria, urinaryretention and urinary infection were the complications observed in 3 out of 10 patients. Themean time to request retreatment was 465 days.Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effectand improved the quality of life of HTLV-1 infected patients with severe overactive bladder
    • ÔÇŽ
    corecore